Minimally invasive post-chemotherapy retroperitoneal lymph node dissection for nonseminoma
Pranav Sharma1,*, Einar F. Sverrisson2,*, Kamran Zargar-Shoshtari1,
Mayer N. Fishman1, Wade J. Sexton1, Shohreh I. Dickinson3,
Philippe E. Spiess1, Michael A. Poch1, Scott M. Gilbert1,
Julio M. Pow-Sang1
Canadian Journal of Urology, Vol.22, No.4, pp. 7882-7889, 2015
Abstract Introduction: We present our experience with
minimally-invasive retroperitoneal lymph node dissection
(MI-RPLND) in the post-chemotherapy (PC) setting for
residual masses in patients with nonseminoma.
Materials and methods: Nineteen men who underwent
PC MI-RPLND (14 – laparoscopic, 5 – robotic) for
low-volume residual disease (no more than 5 clinically
enlarged retroperitoneal masses, size < 5 cm, no adjacent
organ or vascular invasion) between 2006 and 2011
were identified. Clinicodemographic information and
pathological outcomes were reported.
Results: Median age of our study population was
32 (interquartile range [IQR]: 28-39). Most patients
presented with clinical stage II disease (63%) and were… More >